Skip to main content
Clinical Trials/NCT06671314
NCT06671314
Completed
Not Applicable

Adoption of Novel Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Novartis1 site in 1 country42,494 target enrollmentJune 2, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure With Reduced Ejection Fraction
Sponsor
Novartis
Enrollment
42494
Locations
1
Primary Endpoint
Time Spent 30 Days Post-discharge by Discharge Sacubitril/Valsartan (SAC/VAL) Prescription Status
Status
Completed
Last Updated
last year

Overview

Brief Summary

This was a retrospective observational cohort study using patient data from the Get With The Guideline-Heart Failure (GWTG-HF) registry linked to Medicare Fee-for-Service (FFS) claims. The main goal of the study was to compare home-time in Medicare FFS patients with heart failure with mildly reduced or preserved ejection fraction discharged with sacubitril/valsartan versus those discharged without sacubitril/valsartan.

Registry
clinicaltrials.gov
Start Date
June 2, 2022
End Date
October 31, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Novartis
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Time Spent 30 Days Post-discharge by Discharge Sacubitril/Valsartan (SAC/VAL) Prescription Status

Time Frame: Post-discharge at Day 30

Time spent included home-time days, hospital days, skilled nursing facility days, rehab days, other institutional days, and death days. Home-time was defined as the number of days alive and out of the hospital, skilled nursing facility or inpatient rehabilitation facility. SAC/VAL prescription status: with SAC/VAL prescription and without SAC/VAL prescription.

Time Spent 90 Days Post-discharge by Discharge SAC/VAL Prescription Status

Time Frame: Post-discharge at Day 90

Time spent included home-time days, hospital days, skilled nursing facility days, rehab days, other institutional days, and death days. Home-time was defined as the number of days alive and out of the hospital, skilled nursing facility or inpatient rehabilitation facility. SAC/VAL prescription status: with SAC/VAL prescription and without SAC/VAL prescription.

Time Spent 180 Days Post-discharge by Discharge SAC/VAL Prescription Status

Time Frame: Post-discharge at Day 180

Time spent included home-time days, hospital days, skilled nursing facility days, rehab days, other institutional days, and death days. Home-time was defined as the number of days alive and out of the hospital, skilled nursing facility or inpatient rehabilitation facility. SAC/VAL prescription status: with SAC/VAL prescription and without SAC/VAL prescription.

Time Spent 365 Days Post-discharge by Discharge SAC/VAL Prescription Status

Time Frame: Post-discharge at Day 365

Time spent included home-time days, hospital days, skilled nursing facility days, rehab days, other institutional days, and death days. Home-time was defined as the number of days alive and out of the hospital, skilled nursing facility or inpatient rehabilitation facility. SAC/VAL prescription status: with SAC/VAL prescription and without SAC/VAL prescription.

Secondary Outcomes

  • Number of All-cause Mortality Patients at 30, 90, 180, and 365 Days After Discharge With a Sacubitril/Valsartan (SAC/VAL) Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Number of All-cause Mortality Patients at 30, 90, 180, and 365 Days After Discharge Without a SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Number of All-cause Mortality or Heart Failure (HF) Hospitalization Patients at 30, 90, 180, and 365 Days After Discharge With a SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Number of All-cause Mortality or HF Hospitalization Patients at 30, 90, 180, and 365 Days After Discharge Without a SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Number of All-cause Hospitalization Patients at 30, 90, 180, and 365 Days After Discharge With SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Number of All-cause Hospitalization Patients at 30, 90, 180, and 365 Days After Discharge Without a SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Number of Patients Hospitalized for HF at 30, 90, 180, and 365 Days After Discharge With a SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Number of Patients Hospitalized for HF at 30, 90, 180, and 365 Days After Discharge Without a SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Number Patients Hospitalized for Dialysis or End-Stage Kidney Disease at 365 Days After Discharge With and Without a SAC/VAL Prescription(Post-discharge at Day 365)
  • Number Patients Hospitalized for a Metabolic/Nutritional Disorder at 365 Days After Discharge With and Without a SAC/VAL Prescription(Post-discharge at Day 365)
  • Number Patients Hospitalized for Urinary Tract Infection at 365 Days After Discharge With and Without a SAC/VAL Prescription(Post-discharge at Day 365)
  • Number Patients Hospitalized for a Hip Fracture at 365 Days After Discharge With and Without a SAC/VAL Prescription(Post-discharge at Day 365)
  • Difference in Days of Home-time Between Discharge With and Without SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Difference in All-cause Mortality Between Discharge With and Without SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Difference in Composite Measure Between Discharge With and Without SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Difference in All-cause Re-hospitalization Between Discharge With and Without SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Difference in HF Re-hospitalization Between Discharge With and Without SAC/VAL Prescription(Post-discharge at Days 30, 90, 180, and 365)
  • Difference in Hospitalization for Metabolic/Nutritional Disorder Between Discharge With and Without SAC/VAL Prescription(Post-discharge at Day 365)
  • Difference in Hospitalization for Urinary Tract Infection Between Discharge With and Without SAC/VAL Prescription(Post-discharge at Day 365)
  • Difference in Hospitalization for Hip Fracture Between Discharge With and Without SAC/VAL Prescription(Post-discharge at Day 365)
  • Number of All-cause Re-hospitalizations per Patient by Discharge SAC/VAL Prescription Status(Post-discharge at Day 365)
  • Number of HF Re-hospitalizations per Patient by Discharge SAC/VAL Prescription Status(Post-discharge at Day 365)
  • All-cause Re-hospitalization Length of Stay by Discharge SAC/VAL Prescription Status(Post-discharge at Day 365)
  • All-cause HF-related Re-hospitalization Length of Stay by Discharge SAC/VAL Prescription Status(Post-discharge at Day 365)

Study Sites (1)

Loading locations...

Similar Trials